<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We treated 47 adult patients with de novo <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) by an <z:chebi fb="0" ids="48120">anthracycline</z:chebi>-AraC regimen </plain></SENT>
<SENT sid="1" pm="."><plain>Median age was 54, and M/F 1.3 </plain></SENT>
<SENT sid="2" pm="."><plain>At diagnosis, 26 patients had refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with an excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) three had refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA), 11 had refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excessive blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) and seven had <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment was started within 3 months of diagnosis in 30 patients, and after more than 3 months in the 17 remaining patients </plain></SENT>
<SENT sid="4" pm="."><plain>At the <z:hpo ids='HP_0003674'>onset</z:hpo> of treatment, 16 patients had progressed to <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-two patients (47%) reached complete remission (CR), 10 (21%) had hypoplastic <z:hpo ids='HP_0011420'>death</z:hpo> and 15 (32%) had resistant disease </plain></SENT>
<SENT sid="6" pm="."><plain>Median actuarial disease-free interval was 11 months </plain></SENT>
<SENT sid="7" pm="."><plain>Median actuarial survival was 14 months from diagnosis and 10 months from the <z:hpo ids='HP_0003674'>onset</z:hpo> of treatment </plain></SENT>
<SENT sid="8" pm="."><plain>A significantly higher CR rate was found in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> at diagnosis (69% v 19% in patients with other FAB subtypes: P = 0.008), and in patients treated within 3 months of diagnosis </plain></SENT>
<SENT sid="9" pm="."><plain>Using multivariate analysis, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> at diagnosis emerged as the most powerful prognostic factor of CR achievement </plain></SENT>
<SENT sid="10" pm="."><plain>Karyotype was the only significant prognostic factor of disease-free interval, with a median of 16.5 months in patients with <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype versus 4 months in patients with <z:mpath ids='MPATH_458'>normal</z:mpath> findings (P = 0.018) </plain></SENT>
<SENT sid="11" pm="."><plain>A subgroup of 15 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> at diagnosis and <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype, who had a CR rate of 80% and a median actuarial disease-free interval of 18 months, could be identified </plain></SENT>
<SENT sid="12" pm="."><plain>Our results confirm that, overall, intensive chemotherapy has limited efficacy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, especially when compared with allogeneic bone marrow transplantation (BMT) </plain></SENT>
<SENT sid="13" pm="."><plain>Relatively favourable results were obtained in our patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> at diagnosis, however, particularly those with <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype </plain></SENT>
<SENT sid="14" pm="."><plain>In that subgroup, intensive chemotherapy may be recommended, especially before BMT, as a high risk of relapse after BMT in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> allografted as first line therapy has been reported </plain></SENT>
</text></document>